Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.4, 2001-04, pp. : 623-639

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review

By Koeser Leonardo McCrone Paul

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 2, 2013-04 ,pp. : 171-182

Informa Healthcare

Access to resources Recommend Favorite

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Current Neuropharmacology, Vol. 12, Iss. 3, 2014-05 ,pp. : 256-268

Bentham Science Publishers

Access to resources Recommend Favorite

Immunomodulatory drugs in multiple myeloma

By Zangari Maurizio Elice Francesca Tricot Guido

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1411-1418

Informa Healthcare

Access to resources Recommend Favorite

Drugs in Clinical Development for Multiple Sclerosis: Summary and Table

Pharmaceutical Medicine, Vol. 26, Iss. 2, 2012-04 ,pp. : 103-112

Adis International

Access to resources Recommend Favorite

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite